![logo](https://www.bryangarnier.com/wp-content/uploads/2021/04/BG-logo-Tag-cropped.png)
Founded in 2006, GeNeurois a spin-off from the InstitutMérieux group.Itis buildinga technological platform for developing new treatments targeting potential causes of neurological disorders and autoimmune diseases such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy and type1 diabetes.
GeNeuro’s first product, GNbAC1, is a monoclonal antibody that neutralizes a protein expressed by human endogenous retroviruses, which are part of the human genome that is normally silent. GeNeuro believes that this drug candidate could become the first treatment addressing a suspected causal factor of multiple sclerosis and therefore could radically change the way 2.5 million patients suffering from MS are treated.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon, France. It has 20 employees and rights to 16 patent families protecting its technology.